{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:45:48Z","timestamp":1787161548589,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.06.507","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T01:47:58Z","timestamp":1594691278000},"page":"747-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system"],"prefix":"10.1016","volume":"158","author":[{"given":"Jeanna M.","family":"McCuaig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Care","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.06.507_bb0005","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1503\/cmaj.191292","article-title":"Projected estimates of cancer in Canada in 2020","volume":"192","author":"Brenner","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0010","first-page":"7","article-title":"Cancer statics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0015","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0030","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0040","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0045","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counseling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0055","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0060","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database","volume":"66","author":"Moller","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap","volume":"55","author":"McCuaig","year":"2018","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2017.06.002","article-title":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: a Society of Gynecologic Oncology White Paper","volume":"146","author":"Randall","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0080","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0085","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40661-017-0039-8","article-title":"Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature","volume":"4","author":"Frey","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0100","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.10.006","article-title":"Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients","volume":"69","author":"Vergote","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2019.05.012","article-title":"Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives","volume":"140","author":"Gori","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0115","series-title":"Genetic\/Familial High-risk Assessment: Breast, Ovarian, and Pancreatic","author":"NCCN","year":"2019"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnci\/djz080","article-title":"Universal tumor DNA BRCA1\/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition","volume":"112","author":"Vos","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111641","article-title":"Tumor BRCA test for patients with epithelial ovarian cancer: the role of molecular pathology in the era of PARP inhibitor therapy","volume":"11","author":"Fumagalli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PAP.0000000000000177","article-title":"Hereditary breast and ovarian cancer syndrome: moving beyond BRCA1 and BRCA2","volume":"25","author":"Hoang","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0140","series-title":"Fundamentals of Biostatistics","author":"Rosner","year":"2000"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0150","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2015.03.057","article-title":"The sooner the better: genetic testing following ovarian cancer diagnosis","volume":"137","author":"Fox","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jclinpath-2019-206127","article-title":"Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumor tissue analysis","volume":"73","author":"Fumagalli","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12885-019-5535-2","article-title":"Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma","volume":"19","author":"Gornjec","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.06.507_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5114\/pjp.2019.82905","article-title":"Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study","volume":"70","author":"Kowalik","year":"2019","journal-title":"Pol. J. Pathol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0170","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0175","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/jmedgenet-2018-105930","article-title":"Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)","volume":"56","author":"Hauke","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0180","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2013.05.003","article-title":"Keeping it simple: genetics referrals for all invasive serous ovarian cancers","volume":"130","author":"Demsky","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0185","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/IGC.0b013e3182994365","article-title":"Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"23","author":"Novetsky","year":"2013","journal-title":"J. Gynecol. Cancer."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2011.09.040","article-title":"There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","volume":"124","author":"Meiser","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13053-018-0095-z","article-title":"A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer","volume":"16","author":"Vogel","year":"2018","journal-title":"Hered. Cancer Clin. Pract."},{"key":"10.1016\/j.ygyno.2020.06.507_bb0200","series-title":"Handbook of Biological Statistics","author":"McDonald","year":"2014"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:10Z","timestamp":1758772270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820323337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820323337"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.507","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}